Treatment of Low HDL‐C Subjects with the CETP Modulator Dalcetrapib Increases Plasma Campesterol Only in Those Without<i> ABCA1</i> and/or<i> ApoA1</i> Mutations
Crossref DOI link: https://doi.org/10.1007/s11745-014-3956-x
Published Online: 2014-10-04
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Niesor, Eric J.
Kallend, David
Bentley, Darren
Kastelein, John J. P.
Kees Hovingh, G.
Stroes, Erik S. G.
Funding for this research was provided by:
F. Hoffmann-La Roche
Version of Record valid from 2014-10-04